5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma Meeting Abstract
| Authors: | Larkin, J. M. G.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Rutkowski, P.; Lao, C.; Cowey, C. L.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; Ferrucci, P. F.; Smylie, M.; Hogg, D.; Hill, A.; Marquez-Rodas, I.; Haanen, J. B. A. G.; Rizzo, J.; Balogh, A.; Hodi, F. S.; Wolchok, J. |
| Abstract Title: | 5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma |
| Meeting Title: | 44th ESMO Congress (ESMO 2019) |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2019 Sep 27-Oct 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-10-01 |
| Start Page: | mdz394.065 |
| Language: | English |
| ACCESSION: | WOS:000491295500192 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz394.065 |
| Notes: | Meeting Abstract: LBA68_PR -- Appears on pages v904-v905 of the abstract book -- Source: Wos |
